{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:55:47Z","timestamp":1790978147500,"version":"4.1.0"},"reference-count":188,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2024.104265","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T12:08:32Z","timestamp":1733746112000},"page":"104265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?"],"prefix":"10.1016","volume":"54","author":[{"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kortuem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2024.104265_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.lpm.2024.104265_bib0003","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33696\/haematology.4.055","article-title":"Analysis of updates in multiple myeloma treatment and management","volume":"4","author":"Nieto","year":"2023","journal-title":"J Clin Haematol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0005","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.lpm.2024.104265_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072166","article-title":"Bispecific antibodies: a new era of treatment for multiple myeloma","volume":"9","author":"Zhou","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.lpm.2024.104265_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2023.12.003","article-title":"Bispecific antibodies in the treatment of multiple myeloma","author":"Zhou","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.lpm.2024.104265_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1455464","article-title":"Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed\/refractory multiple myeloma","volume":"14","author":"Hamadeh","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/hematology.2022000334","article-title":"Antibodies and bispecifics for multiple myeloma: effective effector therapy","volume":"2022","author":"Cipkar","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0010","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int J Med Sci"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0011","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0012","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"10.1016\/j.lpm.2024.104265_bib0013","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: first Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.lpm.2024.104265_bib0014","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.lpm.2024.104265_bib0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: first Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0016","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14712598.2024.2352591","article-title":"Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma","volume":"24","author":"Jagannath","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.lpm.2024.104265_bib0017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"26","key":"10.1016\/j.lpm.2024.104265_bib0018","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0019","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11523-017-0538-x","article-title":"The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma","volume":"13","author":"Sanchez","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.lpm.2024.104265_bib0021","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0022","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.lpm.2024.104265_bib0023","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0024","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104265_bib0025","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.lpm.2024.104265_bib0026","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.lpm.2024.104265_bib0028","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.lpm.2024.104265_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple myeloma-a promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0030","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0031","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14737140.2019.1586539","article-title":"Anti-BCMA antibodies in the future management of multiple myeloma","volume":"19","author":"Gavriatopoulou","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0032","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2024.104265_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"15","key":"10.1016\/j.lpm.2024.104265_bib0034","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.lpm.2024.104265_bib0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0036","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0037","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0038","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0039","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0041","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0042","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151118","article-title":"Comparative transcriptome analysis of fetal skin reveals key genes related to hair follicle morphogenesis in cashmere goats","volume":"11","author":"Gao","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0044","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5021\/ad.2017.29.5.597","article-title":"Comprehensive Transcriptome profiling of balding and non-balding scalps in trichorhinophalangeal syndrome type I patient","volume":"29","author":"Kim","year":"2017","journal-title":"Ann Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0046","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0047","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.leu.2404445","article-title":"Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma","volume":"21","author":"Ise","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0048","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2008-01-131359","article-title":"FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia","volume":"112","author":"Li","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0049","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.lpm.2024.104265_bib0050","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0051","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.lpm.2024.104265_bib0052","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420980258","article-title":"Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed\/refractory multiple myeloma","volume":"34","author":"Steinhardt","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0053","first-page":"54","article-title":"Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker","volume":"13","author":"Funaro","year":"1999","journal-title":"J Biol Regul Homeost Agents"},{"issue":"7\u20138","key":"10.1016\/j.lpm.2024.104265_bib0054","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s002510050654","article-title":"The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene","volume":"49","author":"Ferrero","year":"1999","journal-title":"Immunogenetics"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0055","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0056","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2024.104265_bib0057","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0058","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0059","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0060","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.lpm.2024.104265_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0062","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"18","key":"10.1016\/j.lpm.2024.104265_bib0063","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1182\/blood-2008-10-183772","article-title":"CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells","volume":"113","author":"Tai","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0064","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0066","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0067","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"26","key":"10.1016\/j.lpm.2024.104265_bib0068","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0069","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062907","article-title":"Investigating T Cell Immunity in Cancer: achievements and Prospects","volume":"22","author":"Zeng","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.lpm.2024.104265_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0072","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/phar.2414","article-title":"Advances in CAR T therapy for hematologic malignancies","volume":"40","author":"Freyer","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0073","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0074","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0075","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0076","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2024.104265_bib0077","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.lpm.2024.104265_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.lpm.2024.104265_bib0079","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key?","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0080","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0081","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T Cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lpm.2024.104265_bib0082","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19515","article-title":"Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: results from a prospective comprehensive biomarker study","author":"Zhou","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2024.104265_bib0083","first-page":"1","article-title":"T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement","author":"Heerma van Voss","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0084","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.0.CO;2-E","article-title":"Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms","volume":"77","author":"Link","year":"1998","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.lpm.2024.104265_bib0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0086","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0087","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187186","article-title":"Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma","volume":"142","author":"Bansal","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.lpm.2024.104265_bib0088","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970664.60500.7f","article-title":"P940: an outpatient model for Teclistamab step-up dosing administration \u2013 initial experiences at fox chase cancer center BMT program","volume":"7","author":"Nina Varshavsky-Yanovsky","year":"2023","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.lpm.2024.104265_bib0089","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/OP.21.00032","article-title":"Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift","volume":"17","author":"Mohan","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0091","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0092","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2024.104265_bib0093","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0094","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 Cohort 2a: efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0095","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173970","article-title":"Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): karMMa-2 Cohort 2c Extended Follow-up","volume":"142","author":"Dhodapkar","year":"2023","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.lpm.2024.104265_bib0096","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2217\/fon-2022-1317","article-title":"Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Martin","year":"2023","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0097","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0098","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"10297","key":"10.1016\/j.lpm.2024.104265_bib0099","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0101","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0102","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed\/Refractory Multiple Myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0103","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","article-title":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.lpm.2024.104265_bib0104","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136748","article-title":"Orvacabtagene Autoleucel (orva-cel; JCARH125): a Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence","volume":"136","author":"Colonna","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0106","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.lpm.2024.104265_bib0107","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0108","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0109","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma (RRMM): updated Results from a Phase 1 Study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma","volume":"1","author":"Simon","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0111","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00108-021-01043-8","article-title":"[CAR T-cell therapy for multiple myeloma]","volume":"62","author":"Zhou","year":"2021","journal-title":"Internist (Berl)"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0112","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0113","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.lpm.2024.104265_bib0116","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0117","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0118","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0119","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0120","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0121","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"S2","key":"10.1016\/j.lpm.2024.104265_bib0122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"P30\u2003SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0123","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","article-title":"MajesTEC-4 (EMN30): a Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0124","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2024.104265_bib0125","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0126","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0127","doi-asserted-by":"crossref","first-page":"TPS8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: an open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0128","doi-asserted-by":"crossref","first-page":"TPS7577","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7577","article-title":"MagnetisMM-30: a phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"42","author":"Lesokhin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0129","doi-asserted-by":"crossref","first-page":"TPS7576","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7576","article-title":"Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38\u2013directed therapy: magnetisMM-32","volume":"42","author":"Schuster","year":"2024","journal-title":"JClin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0130","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.lpm.2024.104265_bib0131","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0132","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-Cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0133","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2022-167008","article-title":"A phase 1 first-in-human study of Abbv-383, a BCMA \u00d7 CD3 bispecific T-Cell-redirecting antibody, as monotherapy in patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.lpm.2024.104265_bib0134","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0136","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: phase 3 Trial of Talquetamab + Daratumumab \u00b1 Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed\/Refractory Multiple Myeloma Following \u22651 Prior Line of Therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0137","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10.1016\/j.lpm.2024.104265_bib0138","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0139","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0141","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): updated Results from an Ongoing Phase I Study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.lpm.2024.104265_bib0142","doi-asserted-by":"crossref","first-page":"TPS8551","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8551","article-title":"GO39775: a multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5\/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma","volume":"38","author":"Cohen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104265_bib0143","unstructured":"SK JB, D Sborov, P Corradini, Y Cohen, A Lesokhin, M Gatt, et al. Cevostamab in patients with RRMM who are triple-classrefractory and have received a prior BCMA-targeted ADC OR CAR T-cell: initial results from the phase I\/II CAMMA 2 STUDY. EHA Annual meeting 2024. 2024."},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0144","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-187409","article-title":"Sequential T-cell engagement for myeloma (\u201cSTEM\u201d) trial: a phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0145","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-186664","article-title":"Dose escalation of ISB 1342, a Novel CD38xCD3 bispecific antibody, in patients with relapsed \/refractory multiple myeloma (RRMM)","volume":"142","author":"Kapoor","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0146","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/HS9.0000000000000575","article-title":"Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma","volume":"5","author":"Ahn","year":"2021","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0147","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.lpm.2024.104265_bib0148","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0149","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0150","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.lpm.2024.104265_bib0151","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0152","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0153","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lpm.2024.104265_bib0154","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"21","key":"10.1016\/j.lpm.2024.104265_bib0155","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","article-title":"Monoallelic deletion of BCMA is a frequent feature in multiple myeloma","volume":"7","author":"Samur","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.lpm.2024.104265_bib0156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104265_bib0157","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouze","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0158","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0159","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.lpm.2024.104265_bib0160","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.lpm.2024.104265_bib0161","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.lpm.2024.104265_bib0162","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/bloodadvances.2024013292","article-title":"Understanding CAR-T therapy in myeloma: 1 cell at a time","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0163","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0164","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.lpm.2024.104265_bib0165","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-Cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.lpm.2024.104265_bib0166","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0167","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189042","article-title":"The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in myeloma patients treated with BCMA bispecific antibodies","volume":"142","author":"Eisele","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0168","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0169","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"15","key":"10.1016\/j.lpm.2024.104265_bib0170","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.lpm.2024.104265_bib0171","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2023011242","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.lpm.2024.104265_bib0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0173","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432204","article-title":"Charting the Course: sequencing Immunotherapy for Multiple Myeloma","volume":"44","author":"Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"S3","key":"10.1016\/j.lpm.2024.104265_bib0174","doi-asserted-by":"crossref","first-page":"e54499e3","DOI":"10.1097\/01.HS9.0000968380.54499.e3","article-title":"P367: long-term outcomes of adults with relapsed or refractory b-cell acute lymphoblastic leukemia treated with Brexucabtagene Autoleucel in zuma-3 by age, prior therapies, and subsequent transplant","volume":"7","author":"Shah","year":"2023","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.lpm.2024.104265_bib0175","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lpm.2024.104265_bib0176","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-185035","article-title":"Efficacy of chimeric antigen receptor T-cell therapy is not impaired by previous bispecific antibody treatment in patients with Large B-cell lymphoma","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lpm.2024.104265_bib0177","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.lpm.2024.104265_bib0178","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0179","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.lpm.2024.104265_bib0180","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.lpm.2024.104265_bib0181","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0182","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0183","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.lpm.2024.104265_bib0184","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.lpm.2024.104265_bib0185","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.lpm.2024.104265_bib0186","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104265_bib0187","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","article-title":"IgG replacement in multiple myeloma","volume":"14","author":"Wonnaparhown","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104265_bib0188","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:47:00Z","timestamp":1741027620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":188,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0755498224000447"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104265","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104265"}}